MicroRNAs as potential biomarkers in malignant pleural mesothelioma

References

• Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: IARC Press; 2015.
   Google Scholar
• Scherpereel A, Astoul P, Baas P, et al; European Respiratory Society/European Society of Thoracic Surgeons Task Force. European Respiratory Society/European Society of Thoracic Surgeons Task F: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–495.
   PubMed Web of Science ®Google Scholar
• Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2012;70(5):743–754.
   Web of Science ®Google Scholar
• Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41(1):27–34.
   PubMed Web of Science ®Google Scholar
• Zimling ZG, Jørgensen A, Santoni-Rugiu E. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. Histopathology. 2012;60(6B):E96–E105.
   Web of Science ®Google Scholar
• Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch Pathol Lab Med. Epub 2015 Aug 19.
   Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48–57.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34(Database issue):D140–D144.
   PubMed Web of Science ®Google Scholar
• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6):590–610.
   PubMed Web of Science ®Google Scholar
• Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol. 2009;62(1):84–88.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145–156.
   PubMed Web of Science ®Google Scholar
• Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48(7):615–623.
   PubMed Web of Science ®Google Scholar
• Busacca S, Germano S, De Cecco L, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42(3):312–319.
   PubMed Web of Science ®Google Scholar
• Balatti V, Maniero S, Ferracin M, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol. 2011;6(5):844–851.
   PubMed Web of Science ®Google Scholar
• Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12(6):771–779.
   Web of Science ®Google Scholar
• Gee GV, Koestler DC, Christensen BC, et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010;127(12):2859–2869.
   PubMed Web of Science ®Google Scholar
• Andersen M, Grauslund M, Muhammad-Ali M, et al. Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma? APMIS. 2012;120(9):767–769.
   Web of Science ®Google Scholar
• Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. J Mol Diagn. 2014;16(4):418–430.
   Web of Science ®Google Scholar
• Miko E, Margitai Z, Czimmerer Z, et al. miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. FEBS Lett. 2011;585(8):1191–1196.
   Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Takahashi T, et al. L-Type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res. 2011;31(12):4075–4082.
   PubMed Web of Science ®Google Scholar
• Li XM, Wang AM, Zhang J, Yi H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol. 2011;28(4):1054–1057.
   Web of Science ®Google Scholar
• Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–152.
   PubMed Web of Science ®Google Scholar
• Feng R, Chen X, Yu Y, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010;298(1):50–63.
   PubMed Web of Science ®Google Scholar
• Parker LH, Schmidt M, Jin SW, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 2004;428(6984):754–758.
   PubMed Web of Science ®Google Scholar
• Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun. 2009;379(3):726–731.
   Web of Science ®Google Scholar
• Andersen M, Trapani D, Ravn J, et al. Methylation-associated silencing of microRNA-126 and its host gene EGFL7 in malignant pleural mesothelioma. Anticancer Res. 2015;35(11):6223–6229.
   Web of Science ®Google Scholar
• Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 2011;6(4):e18232.
   PubMed Web of Science ®Google Scholar
• Tomasetti M, Staffolani S, Nocchi L, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012;45(7–8):575–581.
   PubMed Web of Science ®Google Scholar
• Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 2010;391(3):1483–1489.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Xie H, et al. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem. 2011;351(1–2):157–164.
   PubMed Web of Science ®Google Scholar
• Jiao LR, Frampton AE, Jacob J, et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One. 2012;7(2):e32068.
   PubMed Web of Science ®Google Scholar
• Tomasetti M, Nocchi L, Staffolani S, et al. MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with mitochondrial function. Antioxid Redox Signal. 2014;21(15):2109–2125.
   Web of Science ®Google Scholar
• Bao B, Azmi AS, Ali S, et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta. 2012; 1826(2):272–296.
   PubMed Web of Science ®Google Scholar
• Li T, Li H, Wang Y, et al. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 2011;223(4):519–530.
   Web of Science ®Google Scholar
• Li Z, Li N, Wu M, Li X, Luo Z, Wang X. Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem. 2013;381(1–2):233–242.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang P, Sun T, et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013;15(3):284–294.
   PubMed Web of Science ®Google Scholar
• Guo YH, Zhang C, Shi J, et al. Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR145 through the ERK1/2 in non-small cell lung cancer. Oncol Rep. 2014;31(4):1940–1946.
   Web of Science ®Google Scholar
• Kojima S, Enokida H, Yoshino H, et al. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet. 2014;59(2):78–87.
   PubMed Web of Science ®Google Scholar
• Lu R, Ji Z, Li X, et al. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 2014;140(3):387–397.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun Q, Zhang Z, Ge S, Han ZG, Chen WT. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013; 32(1):61–69.
   PubMed Web of Science ®Google Scholar
• Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010;24(24):2754–2759.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zeng H, Guo Y, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010;29:151.
   Google Scholar
• Cioce M, Ganci F, Canu V, et al. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene. 2014;33(46):5319–5331.
   PubMed Web of Science ®Google Scholar
• Casarsa C, Bassani N, Ambrogi F, et al. Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett. 2011;302(2):136–143.
   Web of Science ®Google Scholar
• Lulla RR, Costa FF, Bischof JM, et al. Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma. 2011;2011:732690.
   PubMedGoogle Scholar
• Gaedcke J, Grade M, Camps J, et al. The rectal cancer microRNAome – microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 2012;18(18):4919–4930.
   PubMed Web of Science ®Google Scholar
• McDermott AM, Miller N, Wall D. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One. 2014;9(1):e87032.
   PubMed Web of Science ®Google Scholar
• Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res. 2015;21(5):1207–1214.
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Nguyen SS, Winbanks CE, et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J. 2014;28(12):5097–5110.
   PubMed Web of Science ®Google Scholar
• Kettunen E, Nissén AM, Ollikainen T, et al. Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer. 2001;91(4):492–496.
   Web of Science ®Google Scholar
• Xiong L, Edwards CK, Zhou L. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci. 2014;15(10):17411–17441.
   Web of Science ®Google Scholar
• Pinheiro C, Longatto-Filho A, Soares TR, et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol. 2012;40(6):478–483.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zheng M, Merritt RE, et al. miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest. 2013;144(5):1632–1643.
   Web of Science ®Google Scholar
• Kirschner MB, Cheng YY, Badrian B, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(7):1184–1191.
   PubMed Web of Science ®Google Scholar
• Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–3135.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102(39):13944–13949.
   PubMed Web of Science ®Google Scholar
• Liu Q, Fu H, Sun F, et al. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 2008;36(16):5391–5404.
   PubMed Web of Science ®Google Scholar
• Pass HI, Goparaju C, Ivanov S, et al. hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 2010;70(5):1916–1924.
   Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805–15810.
   PubMed Web of Science ®Google Scholar
• Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809–22817.
   Web of Science ®Google Scholar
• MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol. 2005;7(6):591–600.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Nabeshima K, Hamasaki M, Shibuta T, Umemura T. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. Med Oncol. 2014;31(12):303.
   Web of Science ®Google Scholar
• He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130–1134.
   PubMed Web of Science ®Google Scholar
• Christoffersen NR, Shalgi R, Frankel LB, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010;17(2):236–245.
   PubMed Web of Science ®Google Scholar
• Wang R, Ma J, Wu Q, et al. Functional role of miR-34 family in human cancer. Curr Drug Targets. 2013;14(10):1185–1191.
   Web of Science ®Google Scholar
• Okada N, Lin CP, Ribeiro MC, et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev. 2014;28(5):438–450.
   PubMed Web of Science ®Google Scholar
• Kubo T, Toyooka S, Tsukuda K, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res. 2011;17(15):4965–4974.
   Web of Science ®Google Scholar
• Muraoka T, Soh J, Toyooka S, et al. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer. 2013;82(3):485–490.
   Web of Science ®Google Scholar
• Maki Y, Asano H, Toyooka S, et al. MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells. Anticancer Res. 2012;32(11):4871–4875.
   Web of Science ®Google Scholar
• Tanaka N, Toyooka S, Soh J, et al. Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncol Rep. 2013;29(6):2169–2174.
   Web of Science ®Google Scholar
• Menges CW, Kadariya Y, Altomare D, et al. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res. 2014;74(4):1261–1271.
   PubMed Web of Science ®Google Scholar
• Ueno T, Toyooka S, Fukazawa T, et al. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Med Okayama. 2014;68(1):23–26.
   PubMed Web of Science ®Google Scholar
• Fassina A, Cappellesso R, Guzzardo V, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25(1):86–99.
   Web of Science ®Google Scholar
• Cheng YY, Kirschner MB, Cheng NC, et al. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. J Thorac Oncol. 2013;8(10):1317–1328.
   Web of Science ®Google Scholar
• Williams M, Kirschner MB, Cheng YY, et al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget. 2015;6(27):23480–23495.
   PubMedGoogle Scholar
• Kao SC, Fulham M, Wong K, et al. A significant metabolic and radiological response after a novel targeted microrna-based treatment approach in malignant pleural mesothelioma. Am J Respir Crit Care Med. 2015;191(12):1467–1469.
   PubMed Web of Science ®Google Scholar
• Haneklaus M, Gerlic M, O’Neill LA, Masters SL. miR-223: infection, inflammation and cancer. J Intern Med. 2013;274(3):215–226.
   PubMed Web of Science ®Google Scholar
• Taïbi F, Metzinger-Le Meuth V, Massy ZA, Metzinger L. miR-223: an inflammatory oncomiR enters the cardiovascular field. Biochim Biophys Acta. 2014;1842(7):1001–1009.
   PubMed Web of Science ®Google Scholar
• Birnie KA, Yip YY, Ng DC, et al. Loss of mir-223 and JNK signalling contribute to elevated stathmin in malignant pleural mesothelioma. Mol Cancer Res. 2015;13(7):1106–1118.
   Web of Science ®Google Scholar
• Ak G, Tomaszek SC, Kosari F, et al. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. 2015;2015:635748.
   PubMed Web of Science ®Google Scholar
• Ramírez-Salazar EG, Salinas-Silva LC, Vázquez-Manríquez ME, et al. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets. Exp Mol Pathol. 2014;97(3):375–385.
   Web of Science ®Google Scholar
• Weber DG, Johnen G, Bryk O, Jöckel KH, Brüning T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma – a pilot study. PLoS One. 2012;7(1):e30221.
   PubMed Web of Science ®Google Scholar
• Weber DG, Casjens S, Johnen G, et al. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis. PLoS One. 2014;9(12):e114483s.
   Web of Science ®Google Scholar
• Santarelli L, Staffolani S, Strafella E, et al. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer. Epub 2015 Sep 25.
   Google Scholar
• Kirschner MB, Cheng YY, Armstrong NJ, et al. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol. 2015;9(3):715–726.
   Web of Science ®Google Scholar
• Sempere LF, Preis M, Yezefski T, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res. 2010;16(16):4246–4255.
   Web of Science ®Google Scholar
• Nielsen BS. MicroRNA in situ hybridization. Methods Mol Biol. 2012;822:67–84.
   PubMedGoogle Scholar
• Nielsen BS, Holsmtrøm K. Combined microRNA in situ hybridization and immunohistochemical detection of protein markers. Methods Mol Biol. 2013;986:353–365.
   PubMedGoogle Scholar
• Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem. 2015;61(1):56–63.
   PubMed Web of Science ®Google Scholar